Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 2/20 | 0.46 |
| ▸ | MGAM | O43451 | 1/20 | 0.46 |
| ▸ | SI | P14410 | 1/20 | 0.46 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.43 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | ALOX15 | P16050 | 3/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.40 |
| ▸ | TSHR | P16473 | 2/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.39 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.39 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | SOAT1 | P35610 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL333918 | 0.98 | GAA (0.44) | GAAMGAMSIMGAM2ALDH1A1 | |
| Hydrochloric Acid SCHEMBL27519019 | 0.83 | SOAT1 (0.48) | GAAMGAMSIMGAM2ALDH1A1 | |
| SCHEMBL7405660 | 0.82 | — | — | |
| SCHEMBL2821 | 0.82 | — | — | |
| SCHEMBL4846715 | 0.82 | — | — | |
| SCHEMBL11543419 | 0.81 | MGAM (0.44) | GAAMGAMSIMGAM2ALDH1A1 | |
| SCHEMBL84736 | 0.81 | GAA (0.44) | GAAMGAMSIMGAM2ALDH1A1 | |
| SCHEMBL11543413 | 0.81 | MGAM (0.44) | GAAMGAMSIMGAM2ALDH1A1 | |
| SCHEMBL13533767 | 0.80 | NAAA (0.46) | ALDH1A1CYP1A2CYP3A4TSHRTDP1 | |
| Hydrochloric Acid SCHEMBL14920670 | 0.80 | MGAM (0.48) | GAAMGAMSIMGAM2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117965123-A | Strong-hydrophobicity two-component joint beautifying agent and preparation method thereof | 潮州市猛犸象建材科技有限公司 | 2024-05-03 | — | — | CN | claimed |
| US-20150322094-A1 | USE OF SUBSTITUTED 2,3-DIHYDRO-1-BENZOFURAN-4-CARBOXYLIC ACIDS OR SALTS THEREOF AS ACTIVE SUBSTANCES AGAINST ABIOTIC PLANT STRESS | BAYER CROPSCIENCE AG (DE) | 2015-11-12 | — | — | US | claimed |
| EP-2892343-A1 | USE OF SUBSTITUTED 2,3-DIHYDRO-1-BENZOFURAN-4-CARBOXYLIC ACIDS OR SALTS THEREOF AS ACTIVE SUBSTANCES AGAINST ABIOTIC PLANT STRESS | Bayer CropScience AG (DE) | 2015-07-15 | — | — | EP | claimed |
| WO-2014037349-A1 | USE OF SUBSTITUTED 2,3-DIHYDRO-1-BENZOFURAN-4-CARBOXYLIC ACIDS OR SALTS THEREOF AS ACTIVE SUBSTANCES AGAINST ABIOTIC PLANT STRESS | BAYER CROPSCIENCE AG (DE) | 2014-03-13 | — | — | WO | claimed |
| CN-117965123-A | Strong-hydrophobicity two-component joint beautifying agent and preparation method thereof | 潮州市猛犸象建材科技有限公司 | 2024-05-03 | — | — | CN | disclosed |
| US-20150322094-A1 | USE OF SUBSTITUTED 2,3-DIHYDRO-1-BENZOFURAN-4-CARBOXYLIC ACIDS OR SALTS THEREOF AS ACTIVE SUBSTANCES AGAINST ABIOTIC PLANT STRESS | BAYER CROPSCIENCE AG (DE) | 2015-11-12 | — | — | US | disclosed |
| EP-2892343-A1 | USE OF SUBSTITUTED 2,3-DIHYDRO-1-BENZOFURAN-4-CARBOXYLIC ACIDS OR SALTS THEREOF AS ACTIVE SUBSTANCES AGAINST ABIOTIC PLANT STRESS | Bayer CropScience AG (DE) | 2015-07-15 | — | — | EP | disclosed |
| WO-2014037349-A1 | USE OF SUBSTITUTED 2,3-DIHYDRO-1-BENZOFURAN-4-CARBOXYLIC ACIDS OR SALTS THEREOF AS ACTIVE SUBSTANCES AGAINST ABIOTIC PLANT STRESS | BAYER CROPSCIENCE AG (DE) | 2014-03-13 | — | — | WO | disclosed |
| US-8222404-B2 | [1,2,4]Thiadiazin-3-yl acetic acid compound and methods of making the acetic acid compound | ANADYS PHARMACEUTICALS, INC. (US) | 2012-07-17 | — | — | US | disclosed |
| US-20120116077-A1 | [1,2,4]THIADIAZIN-3-YL ACETIC ACID COMPOUND[[S]] AND METHODS OF MAKING THE ACETIC ACID COMPOUND | ANADYS PHARMACEUTICALS, INC. (US) | 2012-05-10 | — | — | US | disclosed |
| US-8097613-B2 | [1,2,4]thiadiazine 1,1-dioxide compounds | ANADYS PHARMACEUTICALS, INC. (US) | 2012-01-17 | — | — | US | disclosed |
| WO-2009152166-A1 | [1,2,4]THIADIAZINE 1,1-DIOXIDE COMPOUNDS | ANADYS PHARMACEUTICALS, INC. (US) | 2009-12-17 | — | — | WO | disclosed |
| US-20090306057-A1 | [1,2,4]THIADIAZINE 1,1-DIOXIDE COMPOUNDS | ANADYS PHARMACEUTICALS, INC. (US) | 2009-12-10 | — | — | US | disclosed |
| US-6831199-B1 | In order to avoid bleeding side-effects when treating the conditions associated with integrin alpha v beta 3, it is beneficial to have compounds which are selective antagonists for alpha v beta 3 versus alpha IIb beta 3 | G. D. SEARLE & CO. | 2004-12-14 | — | — | US | disclosed |
| EP-0850221-B1 | META-GUANIDINE, UREA, THIOUREA OR AZACYCLIC AMINO BENZOIC ACID DERIVATIVES AS INTEGRIN ANTAGONISTS | SEARLE & CO (US) | 2001-07-18 | — | — | EP | disclosed |
| US-6028223-A | AN INTEGRIN ANTAGONISTS TREATING BONE DISORDER, PERIODONTAL DISEASE, OSTEOPOROSIS, HUMORAL HYPERCALCEMIA OF MALIGNANCY, PAGET'S DISEASE, TUMOR ANGIOGENESIS, DIABETIC RETINOPATHY, ARTHRITIS, SMOOTH MUSCLE CELL MIGRATION AND RESTENOSIS | G. D. SEARLE & CO. (US) | 2000-02-22 | — | — | US | disclosed |
| EP-0850221-A1 | META-GUANIDINE, UREA, THIOUREA OR AZACYCLIC AMINO BENZOIC ACID DERIVATIVES AS INTEGRIN ANTAGONISTS | G.D. SEARLE & CO. (US) | 1998-07-01 | — | — | EP | disclosed |
| WO-1997008145-A1 | META-GUANIDINE, UREA, THIOUREA OR AZACYCLIC AMINO BENZOIC ACID DERIVATIVES AS INTEGRIN ANTAGONISTS | G.D. SEARLE & CO. (US) | 1997-03-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120116077-A1 | [1,2,4]THIADIAZIN-3-YL ACETIC ACID COMPOUND[[S]] AND METHODS OF MAKING THE ACETIC ACID COMPOUND | ACMSD, ACACA, ALDH1A1 | GAA 751/4885MGAM 3523/4885SI 961/4885 |
| US-20150322094-A1 | USE OF SUBSTITUTED 2,3-DIHYDRO-1-BENZOFURAN-4-CARBOXYLIC ACIDS OR SALTS THEREOF AS ACTIVE SUBSTANCES AGAINST ABIOTIC PLANT STRESS | CAT, HSF1, HPD | GAA 170/4885MGAM 685/4885SI 1042/4885 |
| US-20090306057-A1 | [1,2,4]THIADIAZINE 1,1-DIOXIDE COMPOUNDS | CYP2E1, CYP1A1, CYP1B1 | GAA 3354/4885MGAM 4844/4885SI 4534/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.